European Journal of Cancer
Volume 39, Issue 7 , Pages 899-908 , May 2003

Immunoassays of urokinase (uPA) and its type-1 inhibitor (PAI-1) in detergent extracts of breast cancer tissue

  • A.N Pedersen

      Affiliations

    • Department of Oncology, Finsen Centre, Rigshospitalet, DK-2100 Copenhagen, Denmark
    • Corresponding Author InformationCorresponding author. Tel.: +45-3545-3545; fax: +45-3545-3990
    • ,
  • H.T Mouridsen

      Affiliations

    • Danish Breast Cancer Cooperative Group, Rigshospitalet, DK-2100 Copenhagen, Denmark
    • ,
  • D.Y Tenney

      Affiliations

    • Oncogene Science, Cambridge, USA-02142-1168 MA, USA
    • ,
  • N Brünner

      Affiliations

    • Department of Oncology, Finsen Centre, Rigshospitalet, DK-2100 Copenhagen, Denmark

Received 21 February 2002 ,Revised 13 June 2002 ,Accepted 20 December 2002.

References 

  1. Thomssen C, Jänicke F. Do we need better prognostic factors in node-negative breast cancer? Pro. Eur. J. Cancer. 2000;36:293–298
  2. Andreasen PA, Kjøller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis—a review. Int. J. Cancer. 1997;72:1–22
  3. Hewitt R, Danø K. Stromal cell expression of components of matrix-degrading protease systems in human cancer. Enzyme Protein. 1996;49:163–173
  4. Pedersen AN, Holst-Hansen C, Frandsen TL, Nielsen BS, Stephens RW, Brünner N. The urokinase plasminogen activation system in breast cancer. In:  Bowcock A editors. Breast Cancer. Totowa, NJ 07512: The Humana Press; 1998;p. 325–345
  5. Look MP, Foekens JA. Clinical relevance of the urokinase plasminogen activator system in breast cancer. APMIS. 1999;107:150–159
  6. Pedersen AN, Christensen IJ, Stephens RW, et al.  The complex between urokinase and its type-1 inhibitor in primary breast cancer (relation to survival). Cancer Res. 2000;60:6927–6934
  7. Benraad TJ, Geurtsmoespot J, Grøndahl-Hansen J, et al.  Immunoassays (elisa) of urokinase-type plasminogen activator (upa)—report of an EORTC/Biomed-1 workshop. Eur. J. Cancer. 1996;32A:1371–1381
  8. Sweep F, Geurtsmoespot J, Grebenschikov N, et al.  External quality assessment of transeuropean multicentre antigen determination (ELISA) of urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-1) in human breast cancer tissue extracts. Br. J. Cancer. 1998;78:1434–1441
  9. Jänicke F, Pache L, Schmitt M, et al.  Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1. Cancer Res. 1994;54:2527–2530
  10. Descotes F, Ville G, Bobin JY, Barbier Y, Saez S. Tissue extraction procedures for investigation of urokinase plasminogen activator (uPA) and its inhibitors PAI-1 and PAI-2 in human breast carcinomas. Breast Cancer Res. Treat. 1998;49:135–143
  11. Camiolo SM, Siuta MR, Madeja JM. Improved medium for extraction of plasminogen activator from tissue. Prep. Biochem. 1982;12:297–305
  12. Grøndahl-Hansen J, Agerlin N, Munkholm Larsen P, et al.  Sensitive and specific enzyme-linked immunosorbent assay for urokinase-type plasminogen activator and its application to plasma from patients with breast cancer. J. Lab. Clin. Med. 1988;111:42–51
  13. Rosenquist C, Thorpe SM, Danø K, Grøndahl-Hansen J. Enzyme-linked immunosorbent assay of urokinase-type plasminogen activator (uPA) in cytosolic extracts of human breast cancer tissue. Breast Cancer Res. Treat. 1993;28:223–229
  14. Keijer J, Linders M, van Zonneveld AJ, Ehrlich HJ, de Boer JP, Pannekoek H. The interaction of plasminogen activator inhibitor 1 with plasminogen activators (tissue-type and urokinase-type) and fibrin (localization of interaction sites and physiologic relevance). Blood. 1991;78:401–409
  15. de Witte H, Pappot H, Brünner N, et al.  Elisa for complexes between urokinase-type plasminogen activator and its receptor in lung cancer tissue extracts. Int. J. Cancer. 1997;72:416–423
  16. Pedersen AN, Høyer-Hansen G, Brünner N, et al.  The complex between urokinase plasminogen activator and its type-1 inhibitor in breast cancer extracts quantitated by ELISA. J. Immunol. Meth. 1997;203:55–65
  17. Munch M, Heegaard C, Jensen PH, Andreasen PA. Type-1 inhibitor of plasminogen activators. Distinction between latent, activated and reactive centre-cleaved forms with thermal stability and monoclonal antibodies. FEBS Lett. 1991;295:102–106
  18. Hanano M, Chapman D, Fici GJ, Berger AE, Erickson LA, Levin EG. Detection of specific forms of plasminogen activator inhibitor type-1 by monoclonal antibodies. Fibrinolysis. 1991;5:109–116
  19. Debrock S, Declerck PJ. Characterization of common neoantigenic epitopes generated in plasminogen activator inhibitor-1 after cleavage of the reactive center loop or after complex formation with various serine proteinases. FEBS Lett. 1995;376:243–246
  20. Patston PA, Schapira M. Low-affinity heparin stimulates the inactivation of plasminogen activator inhibitor-1 by thrombin. Blood. 1994;84:1164–1172
  21. van Meijer M, Smilde A, Tans G, et al.  The suicide substrate reaction between plasminogen activator inhibitor 1 and thrombin is regulated by the cofactors vitronectin and heparin. Blood. 1997;90:1874–1882
  22. Pappot H, Gårdsvoll H, Rømer J, et al.  Plasminogen activator inhibitor type 1 in cancer: therapeutic and prognostic implications. Biol. Chem. Hoppe. Seyler. 1995;376:259–267
  23. Christensen L, Wiborg Simonsen AC, Heegaard CW, Moestrup SK, Andersen JA, Andreasen PA. Immunohistochemical localization of urokinase-type plasminogen activator, type-1 plasminogen-activator inhibitor, urokinase receptor and alpha(2)-macroglobulin receptor in human breast carcinomas. Int. J. Cancer. 1996;66:441–452
  24. Harbeck N, Dettmar P, Thomssen C, et al.  Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers (6-year median follow-up). Br. J. Cancer. 1999;80:419–426
  25. Foekens JA, Peters HA, Look MP, et al.  The urokinase system of plasminogen activation and prognosis in breast cancer patients. Cancer Res. 2000;60:636–643
  26. Jänicke F, Prechtl A, Thomssen C, et al.  Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J. Natl. Cancer Inst. 2001;12:913–920
  27. Look MP, van Putten WL, Duffy MJ, et al.  Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in breast cancer patients. J. Natl. Cancer Inst. 2002;2:116–128
  28. Høyer-Hansen G, Ploug M, Behrendt N, Rønne E, Danø K. Cell-surface acceleration of urokinase-catalyzed receptor cleavage. Eur. J. Biochem. 1997;243:21–26
  29. Ugwu F, Van Hoef B, Bini A, Collen D, Lijnen HR. Proteolytic cleavage of urokinase-type plasminogen activator by stromelysin-1 (MMP-3). Biochemistry. 1998;37:7231–7236
  30. Huber K, Kirchheimer JC, Sedlmayer A, Bell C, Ermler D, Binder BR. Clinical value of determination of urokinase-type plasminogen activator antigen in plasma for detection of colorectal cancer (comparison with circulating tumor-associated antigens CA 19-9 and carcinoembryonic antigen). Cancer Res. 1993;53:1788–1793
  31. Casslen B, Bossmar T, Lecander I, Åstedt B. Plasminogen activators and plasminogen activator inhibitors in blood and tumour fluids of patients with ovarian cancer. Eur. J. Cancer. 1994;30A:1302–1309
  32. von Tempelhoff GF, Heilmann L, Dietrich M, Schneider D, Niemann F, Hommel G. Plasmatic plasminogen activator inhibitor activity in patients with primary breast cancer. Thromb. Haemost. 1997;7:606–608
  33. Nielsen HJ, Pappot H, Christensen IJ, et al.  Association between plasma concentrations of plasminogen activator inhibitor-1 and survival in patients with colorectal cancer. Br. Med. J. 1998;316:829–830

PII: S0959-8049(03)00025-X

doi: 10.1016/S0959-8049(03)00025-X

European Journal of Cancer
Volume 39, Issue 7 , Pages 899-908 , May 2003

Article Tools

* Image Usage & Resolution